High cardiovascular complications in systemic lupus erythematosus: Physiopathology and risk management;Le risque cardiovasculaire accru du lupus : données physiopathologiques et thérapeutiques

Nephrologie et Therapeutique

Volumn 5, Issue 7, 2009, Pages 595-602

  Boffa, Jean Jacques ^a,b,c   Rougier, Jean Philippe ^a,b,c   Noël, Nicolas ^a   Ronco, Pierre ^a,b,c  

^a HÔPITAL TENON   (France)

^b INSERM   (France)

^c Urgences Néphrologiques et Transplantation Rénale Hôpital Tenon 4   (France)

Author keywords

Cardiovascular risk; Lupus; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; CORTICOSTEROID; CYCLOPHOSPHAMIDE; HYDROXYCHLOROQUINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY THROMBOSIS; HUMAN; MEDICAL PRACTICE; NONHUMAN; PATHOPHYSIOLOGY; PROPHYLAXIS; RISK MANAGEMENT; SHORT SURVEY; SYSTEMIC LUPUS ERYTHEMATOSUS;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; RISK FACTORS; RISK MANAGEMENT;

EID: 70749120546     PISSN: 17697255     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nephro.2009.06.009     Document Type: Short Survey

References (66)

1. Cohen Tervaert J.W. Translational mini-review series on immunology of vascular disease: accelerated atherosclerosis in vasculitis. Clin Exp Immunol 156 3 (2009) 377-385
2. Björnådal L., Yin L., Granath F., Klareskog L., and Ekbom A. Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population-based study 1964-1995. J Rheumatol 31 4 (2004) 713-719
3. Manzi S., Meilahn E.N., Rairie J.E., Conte C.G., Medsger Jr. T.A., Jansen-McWilliams L., et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 145 5 (1997) 408-415
4. Bruce I.N., Gladman D.D., and Urowitz M.B. Premature atherosclerosis in systemic lupus erythematosus. Rheum Dis Clin North Am 26 2 (2000) 257-278
5. Fischer L.M., Schlienger R.G., Matter C., Jick H., and Meier C.R. Effect of rheumatoid arthritis or systemic lupus erythematosus on the risk of first-time acute myocardial infarction. Am J Cardiol 93 2 (2004) 198-200
6. Ward M.M. Hospital experience and mortality in patients with systemic lupus erythematosus. Arthritis Rheum 42 5 (1999) 891-898
7. Bessant R., Hingorani A., Patel L., MacGregor A., Isenberg D.A., and Rahman A. Risk of coronary heart disease and stroke in a large British cohort of patients with systemic lupus erythematosus. Rheumatology (Oxford) 43 7 (2004) 924-929
8. Urowitz M.B., Ibañez D., and Gladman D.D. Atherosclerotic vascular events in a single large lupus cohort: prevalence and risk factors. J Rheumatol 34 1 (2007) 70-75
9. Bulkley B.H., and Roberts W.C. The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy. A study of 36 necropsy patients. Am J Med 58 2 (1975) 243-264
10. Haider Y.S., and Roberts W.C. Coronary arterial disease in systemic lupus erythematosus; quantification of degrees of narrowing in 22 necropsy patients (21 women) aged 16 to 37 years. Am J Med 70 4 (1981) 775-781
11. Asanuma Y., Oeser A., Shintani A.K., Turner E., Olsen N., Fazio S., et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 349 25 (2003) 2407-2415
12. Roman M.J., Shanker B.A., Davis A., Lockshin M.D., Sammaritano L., Simantov R., et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 349 25 (2003) 2399-2406
13. Maksimowicz-McKinnon K., Magder L.S., and Petri M. Predictors of carotid atherosclerosis in systemic lupus erythematosus. J Rheumatol 33 12 (2006) 2458-2463
14. Roman M.J., Crow M.K., Lockshin M.D., Devereux R.B., Paget S.A., Sammaritano L., et al. Rate and determinants of progression of atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 56 10 (2007) 3412-3419
15. Hahn B.H. Systemic lupus erythematosus and accelerated atherosclerosis. N Engl J Med 349 25 (2003) 2379-2380
16. Manzi S., Selzer F., Sutton-Tyrrell K., Fitzgerald S.G., Rairie J.E., Tracy R.P., et al. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum 42 1 (1999) 51-60
17. Colombo B.M., Murdaca G., Caiti M., Rodriguez G., Grassia L., Rossi E., et al. Intima-media thickness: a marker of accelerated atherosclerosis in women with systemic lupus erythematosus. Ann N Y Acad Sci 1108 (2007) 121-126
18. Thompson T., Sutton-Tyrrell K., Wildman R.P., Kao A., Fitzgerald S.G., Shook B., et al. Progression of carotid intima-media thickness and plaque in women with systemic lupus erythematosus. Arthritis Rheum 58 3 (2008) 835-842
19. Theodoridou A., Bento L., D'Cruz D.P., Khamashta M.A., and Hughes G.R. Prevalence and associations of an abnormal ankle-brachial index in systemic lupus erythematosus: a pilot study. Ann Rheum Dis 62 12 (2003) 1199-1203
20. Selzer F., Sutton-Tyrrell K., Fitzgerald S., Tracy R., Kuller L., and Manzi S. Vascular stiffness in women with systemic lupus erythematosus. Hypertension 37 4 (2001) 1075-1082
21. Belizna C.C., Richard V., Primard E., Kerleau J.M., Cailleux N., Louvel J.P., et al. Early atheroma in primary and secondary antiphospholipid syndrome: an intrinsic finding. Semin Arthritis Rheum 37 6 (2008) 373-380
22. Gómez J., Suárez A., López P., Mozo L., Díaz J.B., and Gutiérrez C. Systemic lupus erythematosus in Asturias. Spain: clinical and serologic features. Medicine (Baltimore) 85 3 (2006) 157-168
23. Cervera R., Khamashta M.A., Font J., Sebastiani G.D., Gil A., Lavilla P., et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 82 5 (2003) 299-308
24. Toloza S.M., Uribe A.G., McGwin Jr. G., Alarcón G.S., Fessler B.J., Bastian H.M., et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. Arthritis Rheum 50 12 (2004) 3947-3957
25. Petri M., Roubenoff R., Dallal G.E., Nadeau M.R., Selhub J., and Rosenberg I.H. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet 348 9035 (1996) 1120-1124
26. de Carvalho J.F., Borba E.F., Viana V.S., Bueno C., Leon E.P., and Bonfá E. Anti-lipoprotein lipase antibodies: a new player in the complex atherosclerotic process in systemic lupus erythematosus?. Arthritis Rheum 50 11 (2004) 3610-3615
27. McMahon M., Grossman J., FitzGerald J., Dahlin-Lee E., Wallace D.J., Thong B.Y., et al. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 54 8 (2006) 2541-2549
28. Asanuma Y., Chung C.P., Oeser A., Shintani A., Stanley E., Raggi P., et al. Increased concentration of proatherogenic inflammatory cytokines in systemic lupus erythematosus: relationship to cardiovascular risk factors. J Rheumatol 33 3 (2006) 539-545
29. Koike T., Bohgaki M., Amengual O., and Atsumi T. Antiphospholipid antibodies: lessons from the bench. J Autoimmun 28 2-3 (2007) 129-133
30. Nojima J., Masuda Y., Iwatani Y., Kuratsune H., Watanabe Y., Suehisa E., et al. Arteriosclerosis obliterans associated with anti-cardiolipin antibody/beta2-glycoprotein I antibodies as a strong risk factor for ischaemic heart disease in patients with systemic lupus erythematosus. Rheumatology (Oxford) 47 5 (2008) 684-689
31. El-Magadmi M., Bodill H., Ahmad Y., Durrington P.N., Mackness M., Walker M., et al. Systemic lupus erythematosus: an independent risk factor for endothelial dysfunction in women. Circulation 110 4 (2004) 399-404
32. Piper M.K., Raza K., Nuttall S.L., Stevens R., Toescu V., Heaton S., et al. Impaired endothelial function in systemic lupus erythematosus. Lupus 16 2 (2007) 84-88
33. Lima D.S., Sato E.I., Lima V.C., Miranda Jr. F., and Hatta F.H. Brachial endothelial function is impaired in patients with systemic lupus erythematosus. J Rheumatol 29 2 (2002) 292-297
34. Kiani A.N., Mahoney J.A., and Petri M. Asymmetric dimethylarginine is a marker of poor prognosis and coronary calcium in systemic lupus erythematosus. J Rheumatol 34 7 (2007) 1502-1505
35. Bultink I.E., Teerlink T., Heijst J.A., Dijkmans B.A., and Voskuyl A.E. Raised plasma levels of asymmetric dimethylarginine are associated with cardiovascular events, disease activity, and organ damage in patients with systemic lupus erythematosus. Ann Rheum Dis 64 9 (2005) 1362-1365
36. Dieudé M., Senécal J.L., and Raymond Y. Induction of endothelial cell apoptosis by heat-shock protein 60-reactive antibodies from anti-endothelial cell autoantibody-positive systemic lupus erythematosus patients. Arthritis Rheum 50 10 (2004) 3221-3231
37. van Paassen P., Duijvestijn A., Debrus-Palmans L., Damoiseaux J., Vroomen M., and Tervaert J.W. Induction of endothelial cell apoptosis by IgG antibodies from SLE patients with nephropathy: a potential role for anti-endothelial cell antibodies. Ann N Y Acad Sci 1108 (2007) 147-156
38. Margutti P., Matarrese P., Conti F., Colasanti T., Delunardo F., Capozzi A., et al. Autoantibodies to the C-terminal subunit of RLIP76 induce oxidative stress and endothelial cell apoptosis in immune-mediated vascular diseases and atherosclerosis. Blood 111 9 (2008) 4559-4570
39. Rajagopalan S., Somers E.C., Brook R.D., Kehrer C., Pfenninger D., Lewis E., et al. Endothelial cell apoptosis in systemic lupus erythematosus: a common pathway for abnormal vascular function and thrombosis propensity. Blood 103 10 (2004) 3677-3683
40. Denny M.F., Thacker S., Mehta H., Somers E.C., Dodick T., Barrat F.J., et al. Interferon-alpha promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis. Blood 110 8 (2007) 2907-2915
41. Esdaile J.M., Abrahamowicz M., Grodzicky T., Li Y., Panaritis C., du Berger R., et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 44 10 (2001) 2331-2337
42. Bruce I.N., Urowitz M.B., Gladman D.D., Ibañez D., and Steiner G. Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study. Arthritis Rheum 48 11 (2003) 3159-3167
43. Costenbader K.H., Liang M.H., Chibnik L.B., Aizer J., Kwon H., Gall V., et al. A pravastatin dose-escalation study in systemic lupus erythematosus. Rheumatol Int 27 11 (2007) 1071-1077
44. Wallace D.J., Metzger A.L., Stecher V.J., Turnbull B.A., and Kern P.A. Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. Am J Med 89 3 (1990) 322-326
45. Rahman P., Gladman D.D., Urowitz M.B., Yuen K., Hallett D., and Bruce I.N. The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs. J Rheumatol 26 2 (1999) 325-330
46. Becker-Merok A., and Nossent J. Prevalence, predictors and outcome of vascular damage in systemic lupus erythematosus. Lupus 18 6 (2009) 508-515
47. Tse K.C., Li F.K., Tang S., Tang C.S., Lai K.N., and Chan T.M. Angiotensin inhibition or blockade for the treatment of patients with quiescent lupus nephritis and persistent proteinuria. Lupus 14 12 (2005) 947-952
48. Teplitsky V., Shoenfeld Y., and Tanay A. The renin-angiotensin system in lupus: physiology, genes and practice, in animals and humans. Lupus 15 6 (2006) 319-325
49. Kanda H., Kubo K., Tateishi S., Sato K., Yonezumi A., Yamamoto K., et al. Antiproteinuric effect of ARB in lupus nephritis patients with persistent proteinuria despite immunosuppressive therapy. Lupus 14 4 (2005) 288-292
50. Wood H.M., and Ernst M.E. Renin-angiotensin system mediators and Raynaud's phenomenon. Ann Pharmacother 40 11 (2006) 1998-2002
51. Costenbader K.H., Kim D.J., Peerzada J., Lockman S., Nobles-Knight D., Petri M., et al. Cigarette smoking and the risk of systemic lupus erythematosus: a meta-analysis. Arthritis Rheum 50 3 (2004) 849-857
52. Freemer M.M., King Jr. T.E., and Criswell L.A. Association of smoking with dsDNA autoantibody production in systemic lupus erythematosus. Ann Rheum Dis 65 5 (2006) 581-584
53. Ghaussy N.O., Sibbitt Jr. W., Bankhurst A.D., and Qualls C.R. Cigarette smoking and disease activity in systemic lupus erythematosus. J Rheumatol 30 6 (2003) 1215-1221
54. Chaiamnuay S., Bertoli A.M., Fernández M., Apte M., Vilá L.M., Reveille J.D., et al. The impact of increased body mass index on systemic lupus erythematosus: data from LUMINA, a multiethnic cohort (LUMINA XLVI) [corrected]. J Clin Rheumatol 13 3 (2007) 128-133
55. Oeser A., Chung C.P., Asanuma Y., Avalos I., and Stein C.M. Obesity is an independent contributor to functional capacity and inflammation in systemic lupus erythematosus. Arthritis Rheum 52 11 (2005) 3651-3659
56. Wahl D.G., Bounameaux H., de Moerloose P., and Sarasin F.P. Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies: do the benefits outweigh the risks? A decision analysis. Arch Intern Med 160 13 (2000) 2042-2048
57. The Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 1991;324(3):150-4.
58. Tam L.S., Gladman D.D., Hallett D.C., Rahman P., and Urowitz M.B. Effect of antimalarial agents on the fasting lipid profile in systemic lupus erythematosus. J Rheumatol 27 9 (2000) 2142-2145
59. Petri M. Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective. Scand J Rheumatol 25 4 (1996) 191-193
60. Rand J.H., Wu X.X., Quinn A.S., Chen P.P., Hathcock J.J., and Taatjes D.J. Hydroxychloroquine directly reduces the binding of antiphospholipid antibody {beta}2-glycoprotein I complexes to phospholipid bilayers. Blood 112 5 (2008) 1687-1695
61. Espinola R.G., Pierangeli S.S., Gharavi A.E., and Harris E.N. Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thromb Haemost 87 3 (2002) 518-522
62. Edwards M.H., Pierangeli S., Liu X., Barker J.H., Anderson G., and Harris E.N. Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. Circulation 96 12 (1997) 4380-4384
63. Romero F., Rodríguez-Iturbe B., Pons H., Parra G., Quiroz Y., Rincón J., et al. Mycophenolate mofetil treatment reduces cholesterol-induced atherosclerosis in the rabbit. Atherosclerosis 152 1 (2000) 127-133
64. Kaczmarek I., Ertl B., Schmauss D., Sadoni S., Knez A., Daebritz S., et al. Preventing cardiac allograft vasculopathy: long-term beneficial effects of mycophenolate mofetil. J Heart Lung Transplant 25 5 (2006) 550-556
65. Tian N., Gu J.W., Jordan S., Rose R.A., Hughson M.D., and Manning Jr. R.D. Immune suppression prevents renal damage and dysfunction and reduces arterial pressure in salt-sensitive hypertension. Am J Physiol Heart Circ Physiol 292 2 (2007) H1018-H1025
66. Herrera J., Ferrebuz A., MacGregor E.G., and Rodriguez-Iturbe B. Mycophenolate mofetil treatment improves hypertension in patients with psoriasis and rheumatoid arthritis. J Am Soc Nephrol 17 12 Suppl. 3 (2006) S218-S225